In January of 2020, Tarsus raised $60 million Series B financing round to initiate Phase 2b/3 trial in the U.S. of their lead product TP-03 for Demodex blepharitis. In this episode, Bobby Azamian shares his background and path to ophthalmology, details on their clinical trials and practical advice for entrepreneurs.Interviewer:Ehsan Sadri, MDManaging PartnerVisionary MD Eye Laser instituteGuest:Bobak Azamian, MD, PhDCEOTarsusAre you interested in being an OIS Podcast guest or interested in presenting at one of our upcoming showcases?Visit OIS.net for more info – https://ois.net/get-involved